Abstract 2302: Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review

Abstract Introduction: Cervical cancer is the fourth most common cancer and the fourth leading cause of cancer-related death in women, worldwide. Advances in understanding the molecular biology of premalignant cervical lesions have shown that not all low-grade squamous intraepithelial lesions progress to high-grade squamous intraepithelial lesions and, nor will all of these progress to invasive carcinoma. Prognostic biomarkers make it possible to predict the evolution of high-grade squamous intraepithelial lesions and to identify patients at risk of progression to cancer. Biomarkers related to cell proliferation, DNA methylation, and immune regulation have been proposed, although the evidence is extensive and heterogeneous.We conducted a scoping review to search possible promising biomarkers for risk stratification of high-grade squamous intraepithelial lesions progression. Methods: We followed the methodological framework proposed by Arksey and O’Malley and the guidelines established by PRISMA-ScR. A systematic literature search was conducted in Web of Science, PubMed, and Embase using terms such as “high-grade squamous intraepithelial lesions,” “uterine cervical neoplasms,” “biomarkers,” and “disease progression,” from the inception of each database through May 30, 2025. Results: A total of 11,795 articles were identified; after removing 4,447 duplicates with Rayyan®, 7,348 records remained for title and abstract screening. Of these, 619 were assessed in full text and 34 were included in the qualitative synthesis. In high-grade squamous intraepithelial lesions, p16, Ki-67, and detection of E6/E7 were associated with a higher risk of progression, whereas FAM19A4/miR124-2 methylation was associated with regression. Overexpression of markers such as RFC4, RIPK4, ATAD2, EZH2, IMP3, ADAR1, AEG-1, TK1, PAK1, aPKCι/λ, tenascin-C, HABP1, CFTR, CPE, and the Np63/TAp63 ratio was linked to greater aggressiveness, lymph node metastasis, and poorer survival. Conclusions: The most promising biomarkers for risk stratification of high-grade squamous intraepithelial lesions progression are p16, Ki-67, FAM19A4/miR124-2 methylation, and E6/E7 mRNA. Their combined use could optimize the identification of patients who require active management and reduce overtreatment in cases with a high probability of regression. Standardization of methods and cut-off values is required for their clinical validation. Citation Format: Luis Giraldo-Barrios, Salome Andrade-Romero, Jonathan Villalobos-Escorcia, Gerardo Barboza-Guevara, Ines Benedetti, . Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2302.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-2302
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 2302: Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review

Luis Gabriel Giraldo-Barrios, Inés Benedetti, Gerardo Barboza-Guevara, Jonathan Villalobos-Escorcia et al.
Cancer Research
Cervical Cancer and HPV Research
article

Abstract 2302: Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review

Luis Gabriel Giraldo-Barrios, Inés Benedetti, Gerardo Barboza-Guevara, Jonathan Villalobos-Escorcia, Salome Andrade-Romero
article en

Abstract

Abstract Introduction: Cervical cancer is the fourth most common cancer and the fourth leading cause of cancer-related death in women, worldwide. Advances in understanding the molecular biology of premalignant cervical lesions have shown that not all low-grade squamous intraepithelial lesions progress to high-grade squamous intraepithelial lesions and, nor will all of these progress to invasive carcinoma. Prognostic biomarkers make it possible to predict the evolution of high-grade squamous intraepithelial lesions and to identify patients at risk of progression to cancer. Biomarkers related to cell proliferation, DNA methylation, and immune regulation have been proposed, although the evidence is extensive and heterogeneous.We conducted a scoping review to search possible promising biomarkers for risk stratification of high-grade squamous intraepithelial lesions progression. Methods: We followed the methodological framework proposed by Arksey and O’Malley and the guidelines established by PRISMA-ScR. A systematic literature search was conducted in Web of Science, PubMed, and Embase using terms such as “high-grade squamous intraepithelial lesions,” “uterine cervical neoplasms,” “biomarkers,” and “disease progression,” from the inception of each database through May 30, 2025. Results: A total of 11,795 articles were identified; after removing 4,447 duplicates with Rayyan®, 7,348 records remained for title and abstract screening. Of these, 619 were assessed in full text and 34 were included in the qualitative synthesis. In high-grade squamous intraepithelial lesions, p16, Ki-67, and detection of E6/E7 were associated with a higher risk of progression, whereas FAM19A4/miR124-2 methylation was associated with regression. Overexpression of markers such as RFC4, RIPK4, ATAD2, EZH2, IMP3, ADAR1, AEG-1, TK1, PAK1, aPKCι/λ, tenascin-C, HABP1, CFTR, CPE, and the Np63/TAp63 ratio was linked to greater aggressiveness, lymph node metastasis, and poorer survival. Conclusions: The most promising biomarkers for risk stratification of high-grade squamous intraepithelial lesions progression are p16, Ki-67, FAM19A4/miR124-2 methylation, and E6/E7 mRNA. Their combined use could optimize the identification of patients who require active management and reduce overtreatment in cases with a high probability of regression. Standardization of methods and cut-off values is required for their clinical validation. Citation Format: Luis Giraldo-Barrios, Salome Andrade-Romero, Jonathan Villalobos-Escorcia, Gerardo Barboza-Guevara, Ines Benedetti, . Prognostic biomarkers associated with the progression of cervical premalignant lesions to cancer: A scoping review [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 2302.

Cancer ResearchVol. 86(7_Supplement)
University of Cartagena (CO)
Good health and well-being
Openalex Percentile: Top 5%
Cervical Cancer and HPV Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.